Drugs in clinical trial would qualify for approval if people at very early stages of the disease subtly improved their performance on memory or reasoning tests, even before they developed any obvious impairments. Companies would not have to show that the drugs improved daily, real-world functioning.Thanks for the money for nothing!
“This is really a huge advance,” said Dr. Eric Siemers, senior medical director for the Alzheimer’s disease team at Eli Lilly & Company. “Kudos to the F.D.A.”
Good grief- do those people not watch horror movies?
Something is going to go terribly wrong, and in ten years we are going to have a bunch of elderly face-eating zombies to deal with...
